Stimulation of functional recovery via the mechanisms of neurorepair by S-nitrosoglutathione and motor exercise in a rat model of transient cerebral ischemia and reperfusion

Restor Neurol Neurosci. 2012;30(5):383-96. doi: 10.3233/RNN-2012-110209.

Abstract

Purpose: Stroke disability stems from insufficient neurorepair mechanisms. Improvement of functions has been achieved through rehabilitation or therapeutic agents. Therefore, we combined exercise with a neurovascular protective agent, S-nitrosoglutathione (GSNO), to accelerate functional recovery.

Methods: Stroke was induced by middle cerebral artery occlusion for 60 min followed by reperfusion in adult male rats. Animals were treated with vehicle (IR group), GSNO (0.25 mg/kg, GSNO group), rotarod exercise (EX group) and GSNO plus exercise (GSNO+EX group). The groups were studied for 14 days to determine neurorepair mechanisms and functional recovery.

Results: Treated groups showed reduced infarction, decreased neuronal cell death, enhanced neurotrophic factors, and improved neurobehavioral functions. However, the GSNO+EX showed greater functional recovery (p < 0.05) than the GSNO or the EX group. A GSNO sub group, treated 24 hours after IR, still showed motor function recovery (p < 0.001). The protective effect of GSNO or exercise was blocked by the inhibition of Akt activity.

Conclusions: GSNO and exercise aid functional recovery by stimulating neurorepair mechanisms. The improvements by GSNO and exercise depend mechanistically on the Akt pathway. A combination of exercise and GSNO shows greater functional recovery. Improved recovery with GSNO, even administered 24 hours post-IR, demonstrates its clinical relevance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Analysis of Variance
  • Animals
  • Apoptosis / drug effects
  • Brain Infarction / etiology
  • Brain Infarction / pathology
  • Brain Infarction / prevention & control
  • Brain-Derived Neurotrophic Factor / metabolism
  • Caspase 3 / metabolism
  • Chromones / administration & dosage
  • Disease Models, Animal
  • Drug Administration Schedule
  • Enzyme Inhibitors / administration & dosage
  • Exercise Therapy / methods*
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / physiology
  • Glial Fibrillary Acidic Protein / metabolism
  • In Situ Nick-End Labeling
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Infarction, Middle Cerebral Artery / pathology
  • Infarction, Middle Cerebral Artery / rehabilitation*
  • Locomotion / drug effects
  • Male
  • Morpholines / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Oncogene Protein v-akt / metabolism
  • Phosphopyruvate Hydratase / metabolism
  • Platelet Endothelial Cell Adhesion Molecule-1 / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, trkB / metabolism
  • Recovery of Function* / drug effects
  • Recovery of Function* / physiology
  • Reperfusion*
  • S-Nitrosoglutathione / therapeutic use*
  • Severity of Illness Index
  • Time Factors

Substances

  • Brain-Derived Neurotrophic Factor
  • Chromones
  • Enzyme Inhibitors
  • Glial Fibrillary Acidic Protein
  • Morpholines
  • Neuroprotective Agents
  • Platelet Endothelial Cell Adhesion Molecule-1
  • 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
  • S-Nitrosoglutathione
  • Receptor, trkB
  • Oncogene Protein v-akt
  • Caspase 3
  • Phosphopyruvate Hydratase